2Q16 Public-Private Partnership Roundup
Highlights of public-private partnerships from 2Q16
A new consortia revival helped boost public-private partnerships (PPPs) in 2Q16 to the highest total in two years. Newly announced preclinically focused deals jumped 30% over the relatively sluggish first quarter, from 56 PPPs to 71.
In previous analyses, stakeholders told BioCentury the field was starting to show "consortia fatigue." In 2015, BioCentury Innovations tracked 20 PPP consortia - defined as new partnerships involving four or more academic or industry partners. That trend spilled into this year, with only three new consortia announced in 1Q16. However, in 2Q16, nine new consortia were announced, including seven composed mostly of U.S.-based academic or industry partners (see Figure: PPP Consortia).
Seven of the consortia announced last quarter were organized explicitly around cancer, plus an eighth that developed a roadmap for large-scale manufacturing of cell-based therapies in cancer and several other diseases. Of the cancer-focused consortia, all but one - the EU-based CanPathPro Consortium - were based in the U.S., although only one was explicitly tied to the White House's Cancer Moonshot initiative, announced in January.
For standard PPPs, University of Pennsylvania launched more than any other academic institution with six new PPPs; NIH had five, thanks in part to two tied to the National Cancer Institute (NCI)'s involvement in the Cancer Moonshot initiative. While big pharmas took part in 14 of the 71 deals, the majority involved smaller biotechs.
It remains unclear whether or when the U.K.'s Brexit decision to leave the European Union, following its June 23 referendum, will impact dealmaking in this space. Of Europe's 52 academic or industry partners involved in PPPs during 2Q16, 14 reside in the U.K.,